Gentamycin is an Aminoglycoside

Gentamycin is an Aminoglycoside



Gentamycin is an Aminoglycoside.

They are antibiotics used to treat infections caused by gram negative bacteria (Escherichia coli, pseudomonas and salmonella) as well as gram positive bacteria (staphyloccus aureas).

Enterrococci are generally resistant to aminoglycosides. Aminoglycosides are used in the short-term treatment of many serious infections (e.g. septicemia) only when other less toxic anti-infectives are inffeffective or contraindicated.

Because of poor absorption from the gastrointestinal (G I ) tract, amninoglycosides are usually administered parentally, (i.e., I M or I V).

Serum levels (peak and trough) are often drawn to determine optimal dosing and lessen the risk of side effects. These levels measure the amount of drug in the blood at different times, and are used to adjust the subsequent doses and/ or the frequency of doses. Peak serum levels are drawn 1 hour after the start of the infusion or I M injection of the third doses of aminoglycoside; trough levels are drawn 30 minutes before the next dose.

Side effects from aminoglycosides, especially in older adults, dehydrated patients, or those with renal or hearing impairment, can include:

–          Nephrotoxicity, including pathological kidney condition, can be reversed upon discontinuation.

–          Ototoxicity, both auditory and vestibular (vertigo) may be permanent.

–          Neuromuscular blocking, including respiratory paralysis

–          CNS symptoms include headache, tremor, lethargy, numbness seizures

–          Blurred vision, rash, or urticaria


| Published on September 20th, 2010 at 11:33 am | Article of: Health | Resource for: , , |

Feel free to leave suggestions, ask any questions for help or simply talk about things discussed here.

2 Responses to “Gentamycin is an Aminoglycoside”

    Kolawole on October 23, 2015 :

    In my opinion, once daily dose with aarccute monitoring of drug levels should be considered relatively safe.Whenever indicated, I use to administer a single empyrical aminoglycoside dose as suggested by Kirkpatrick (Br J Clin Pharmacol). After 24 h, I look at the aminoglycoside trough levels. At second administration, the drug is dosed using a simple software for pharmacocinetic model (for example, JPKD which is free online). Then, trough levels are closely monitored to make any change in drug dose. With an appropriate fluid administration, I administered such a treatment even in pts with a marked reduction in GFR (CKD stage 4, 5) without evidence of significant toxicity.

    Shah on November 26, 2015 :

    What about giving gcymatnein in a patient with AKI who is completely anuric (blood culture positive for klebsiella sensitive only to gcymatnein)? This patient has dialysis every day and the drug is given after dialysis(140mg once daily). In this case that the GFR is practically zero do you think that is possible for the gcymatnein to make toxic levels in the PCT lumen and to deteriorate the AKI? In my opinion no-but i would like yours .

Your Comments, Tips, Tricks and Solutions for